Medicare Fee-for-Service Enrollees with Primary Acute Myeloid Leukemia: An Analysis of Treatment Patterns, Survival, and Healthcare Resource Utilization and Costs

Overview of attention for article published in Applied Health Economics and Health Policy, May 2013

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (86th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news: 1 news outlet

policy: 1 policy source

Citations

dimensions_citation: 128 Dimensions

Readers on

mendeley: 182 Mendeley

Summary News Policy documents Dimensions citations

So far, Altmetric has seen 2 policy documents that reference this research output.

Gilteritinib for treating relapsed or refractory acute myeloid leukaemia : Appraisal consultation committee papers

Cited by National Institute for Health and Care Excellence on 08 Jan 2020

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts: Committee papers

Cited by National Institute for Health and Care Excellence on 08 Apr 2016

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.